We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Boston Scientific (BSX - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Boston Scientific is a member of the Medical sector. This group includes 1011 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Boston Scientific is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BSX's full-year earnings has moved 2.2% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, BSX has returned 1.5% so far this year. In comparison, Medical companies have returned an average of -4.7%. As we can see, Boston Scientific is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Aclarion, Inc. (ACON - Free Report) . The stock has returned 107.2% year-to-date.
Over the past three months, Aclarion, Inc.'s consensus EPS estimate for the current year has increased 11%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Boston Scientific is a member of the Medical - Products industry, which includes 82 individual companies and currently sits at #90 in the Zacks Industry Rank.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Boston Scientific (BSX - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Boston Scientific is a member of the Medical sector. This group includes 1011 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Boston Scientific is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BSX's full-year earnings has moved 2.2% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, BSX has returned 1.5% so far this year. In comparison, Medical companies have returned an average of -4.7%. As we can see, Boston Scientific is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Aclarion, Inc. (ACON - Free Report) . The stock has returned 107.2% year-to-date.
Over the past three months, Aclarion, Inc.'s consensus EPS estimate for the current year has increased 11%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Boston Scientific is a member of the Medical - Products industry, which includes 82 individual companies and currently sits at #90 in the Zacks Industry Rank.